Hydroxychloroquine as Therapeutic Option in COVID-19: Analysis of Suspected Cardiovascular Adverse Drug Events Reported in the VigiBase

Background: Hydroxychloroquine(HCQ), one of the repurposed drugs in COVID-19, has several known cardiovascular(CVS) toxicities.
 Methods: VigiBase data were used to analyze reported ADEs linked HCQ. The analyzed based on age, gender, and seriousness at System Organ Classification level individual Preferred Term level.
 Results: majority above 18 years(91.6%) from Europe(41.6%). A total 5,315 associated with HCQ use COVID-19. Of these, 918 attributed CVS 773 patients. Grossly, concomitant azithromycin(AZM), only 40 solely due serious (69.3%) resolved afterward (51%). In ADEs, there 366 cardiac disorders, 38 vascular 514 under investigation. Among palpitation was most typical (N=65), followed by bradycardia(N=44) tachycardia(N=33). arrhythmias, QT prolongation (N=469), atrial fibrillation (N=25), ventricular tachycardia(N=16) common. odds developing increased patients aged 45-64 years(OR=1.75; p= 0.015) >65 years(OR=1.93, p=0.003) as compared younger ones.
 Conclusion: Hydroxychloroquine toxicities risk co-administering AZM makes physicians cautious while prescribing COVID-19 patients.
 Bangladesh Journal Medical Science Vol.20(4) 2021 p.897-910